Advances in Ovarian Cancer Research: From Biology to Therapeutics

Dear colleagues,

Recently, substantial progress has been made in treating ovarian cancer, predominantly based on the identification of new molecular targets. For example, PARP inhibitors have been successful largely due to their efficacy in cancers that harbor BRCA mutations or evidence of deficiency in the homologous recombination DNA repair pathway. This collection of articles will address the biological discoveries leading to the next breakthroughs in ovarian cancer research and treatment. Authors are encouraged to submit research studies with translational potential, especially those that include novel biomarkers for treatment effects. This topic thus provides a framework for integrating discoveries at the bench and the bedside.

Dr. Christina M. Annunziata
Dr. Adam R. Karpf
Topic Editors

Deadline for abstract submissions: 28 February 2022.
Deadline for manuscript submissions: 31 May 2022.

Topic Board

Dr. Christina M. Annunziata
E-Mail Website
Topic Editor-in-Chief
National Cancer Institute, Bethesda, MD, USA
Interests: ovarian cancer; clinical trials; NF-kappaB; immunotherapy
Special Issues and Collections in MDPI journals
Dr. Adam R. Karpf
E-Mail Website
Topic board member
Eppley Institute and Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA
Interests: ovarian cancer; DNA replication stress; DNA methylation; FOXM1


  • ovarian cancer
  • translational research
  • biomarkers
  • genetics
  • epigenetics
  • clinical trials
  • tumor biology
  • drug discovery

Relevant Journals List

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
4.879 3.2 2011 16.29 Days 2000 CHF Submit
6.639 4.4 2009 17.04 Days 2200 CHF Submit
6.600 - 2012 15.34 Days 2000 CHF Submit
Current Oncology
3.677 3.8 1994 19.84 Days 1600 CHF Submit

Published Papers

This Topic is now open for submission.
Back to TopTop